Mycoplasma

The New First Response™ Advertising Campaign, Stories of Home, Highlights a Couple’s Journey Through Infertility: The Story of Emily and Ben

Retrieved on: 
Thursday, July 11, 2019

One of these journeys portrays the story of Emily and Ben and shines a light on the struggles that 1 in 8 couples* experience when faced with infertility.

Key Points: 
  • One of these journeys portrays the story of Emily and Ben and shines a light on the struggles that 1 in 8 couples* experience when faced with infertility.
  • First Response has been a longtime partner of RESOLVE: The National Infertility Association, says Stephanie Berez, Director of Marketing, First Response.
  • Our new advertising pays homage to the many couples navigating infertility.
  • While the ad concludes with Emily and Ben finding success, it is also important to acknowledge the many family building alternatives that couples can consider.

In-Vitro Fertilization Services Market to Cross $17 Billion by 2025: Global Market Insights, Inc.

Retrieved on: 
Friday, June 28, 2019

Global In-vitro Fertilization Services Market is poised to surpass USD 17 billion by 2025; according to a new research study published by Global Market Insights, Inc.

Key Points: 
  • Global In-vitro Fertilization Services Market is poised to surpass USD 17 billion by 2025; according to a new research study published by Global Market Insights, Inc.
  • Increasing prevalence of infertility issues will significantly contribute to in-vitro fertilization services market growth in forthcoming years.
  • Also, irregular reimbursement scenario, specifically in the developing economies will further limit in-vitro fertilization services market growth.
  • U.S. in-vitro fertilization services market accounted for USD 2.7 billion in 2018.

RESOLVE: The National Infertility Association Participates in Global Research Collaboration

Retrieved on: 
Tuesday, June 25, 2019

MCLEAN, Va., June 25, 2019 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association is pleased to announce the release of the global report "Priority Setting Partnership for Infertility: What should infertility research focus on next?"

Key Points: 
  • MCLEAN, Va., June 25, 2019 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association is pleased to announce the release of the global report "Priority Setting Partnership for Infertility: What should infertility research focus on next?"
  • "I'm so proud that RESOLVE is part of a global effort to identify and answer fundamental questions about the treatment of infertility."
  • The full report, 'Priority Setting Partnership for Infertility: What should infertility research focus on next?
  • ', can be downloaded from: http://tiny.cc/qhte8y
    About RESOLVE: The National Infertility Association: Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established, nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for men and women experiencing infertility or other reproductive disorders.

The Maryland Corks with Cade Fundraiser Supports Grants of Up to $10,000 for Family Building and Brings Wine, Live Music, and Great Food to Frederick, Maryland

Retrieved on: 
Monday, June 24, 2019

Attendees will sample wines from the vineyard, enjoy live music from several local bands, feast on gourmet foods, and celebrate family building and OVERCOMING infertility.

Key Points: 
  • Attendees will sample wines from the vineyard, enjoy live music from several local bands, feast on gourmet foods, and celebrate family building and OVERCOMING infertility.
  • The Grants, which provide up to $10,000 for fertility treatment, are specifically designated for any family with infertility in the US.
  • Purchase tickets to the Maryland Corks with Cade or make a donation in support of these grants at CadeFoundation.org.
  • To apply for a Family Building Grant , please submit an application for the Cade Foundation Family Building Grant at cadefoundation.org/grants.

UMN Medical School Report Shows Sexually Transmitted Infections at All-Time High Among MN Youth

Retrieved on: 
Tuesday, June 18, 2019

MINNEAPOLIS, June 18, 2019 /PRNewswire/ -- While pregnancy and birth rates continue to decline for 15 to 19-year-olds, putting them at historic lows, Minnesota youth are contracting sexually transmitted infections (STI) at alarmingly high rates.

Key Points: 
  • MINNEAPOLIS, June 18, 2019 /PRNewswire/ -- While pregnancy and birth rates continue to decline for 15 to 19-year-olds, putting them at historic lows, Minnesota youth are contracting sexually transmitted infections (STI) at alarmingly high rates.
  • The HYD-PRC's report notes that Minnesota youth are disproportionately impacted by sexually transmitted infections.
  • Birth rates for American Indian, black, and Latinx youth are higher than for white youth.
  • The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians.

Asia-Pacific Infectious Disease Point-of-Care Testing 2019-2023: Rising Prevalence of TB, HIV, and Hepatitis, Accompanied by the Development of Portable POCT Devices

Retrieved on: 
Monday, June 17, 2019

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market.

Key Points: 
  • This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market.
  • The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests.
  • The Asia-Pacific shows the highest prevalence of infectious diseases, such as tuberculosis (TB), hepatitis, and sexually transmitted infections (STIs).
  • With the rising disease prevalence, companies are shifting their business models to a more consumer-oriented approach.

Shady Grove Fertility Advocates on Capitol Hill for the Infertility Community, 2019 Advocacy Day, May 16

Retrieved on: 
Friday, May 3, 2019

WASHINGTON, May 3, 2019 /PRNewswire-PRWeb/ -- Shady Grove Fertility (SGF) , a visionary partner of RESOLVE: The National Infertility Association's Advocacy Day, invites the community to join the movement on Advocacy Day, May 16, 2019.

Key Points: 
  • WASHINGTON, May 3, 2019 /PRNewswire-PRWeb/ -- Shady Grove Fertility (SGF) , a visionary partner of RESOLVE: The National Infertility Association's Advocacy Day, invites the community to join the movement on Advocacy Day, May 16, 2019.
  • Advocacy Day is our chance to empower the infertility community and make sure our voices are heard on Capitol Hill.
  • I look forward to joining my fellow peers and patients to bring attention to these important issues," says Brad Swelstad, M.D.
  • , Chief Medical Officer of Shady Grove Fertility and a member of the RESOLVE Board of Directors.

Global Sexually Transmitted Diseases (STD) Treatment Market to 2023: Approval of Drugs and a Strong Pipeline - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GSK, J&J, & Merck & Co

Retrieved on: 
Thursday, May 2, 2019

DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
  • One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline.
  • One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs.

Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019

Retrieved on: 
Tuesday, April 30, 2019

The archived webcast will be available via the aforementioned URLs.

Key Points: 
  • The archived webcast will be available via the aforementioned URLs.
  • Evofem Biosciences, Inc., is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections ("STIs").
  • Amphora is a registered trademark and Multipurpose Vaginal pH Regulator is a trademark of Evofem Biosciences, Inc.

Global Sexually Transmitted Diseases (STD) Treatment Markets 2018-2019 & Forecast to 2023 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2019

The "Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
  • One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline.
  • One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs.